ArticleClinical medicine insights. Case reports2026
Paraneoplastic Pemphigus Associated With Renal Cell Carcinoma. Rare Case Report and Literature Review.
Article in Clinical medicine insights. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Paraneoplastic pemphigus (PNP) is an uncommon autoimmune blistering disorder frequently associated with underlying malignancies. Renal cell carcinoma (RCC) is the most common primary renal cancer. It is associated with a wide range of paraneoplastic syndromes, but occasionally presents as a dermatological finding. Case presentation: A 56-year-old woman with severe oral and cutaneous lesions was diagnosed with PNP associated with renal cell carcinoma (RCC). The patient was treated with 1 g of rituximab as an infusion, and after two weeks, another dose of 1 g of rituximab was administered in combination with steroids (prednisolone 0.5 mg/kg) until control, then gradually decreasing by 25% each month, until we reached 5 mg/day. The patient achieved complete clinical remission at 6 months; however, long-term outcomes remain unknown because she was subsequently lost to follow-up. Conclusion: A comprehensive workup is crucial for diagnosing the underlying tumor associated with this phenomenon. Rituximab- and steroid-based therapies may be effective in controlling PNP symptoms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.